In the spirit of win-win collaboration, SanegeneBio has been proactively exploring the partnering opportunity with other pharmaceutical and biotech companies. SanegeneBio is open to different types of collaboration, e.g. platform technology, asset licensing, co-development etc., and aims to leverage its discovery platform and early development advantages to work together with partners with synergized strength in clinical and commercialization. By bringing the capabilities of both SanegeneBio and partners, we are dedicated to accelerate the RNAi drug development and expand market access to benefit more patients with unmet medical needs in cardiovascular and metabolic diseases, immunology-related diseases, and nervous system diseases.
